10/28/2019 | DD | Market Commentary: PG&E dives as blackouts, wildfires persist; McDermott declines after ratings downgrade
|
10/9/2019 | DD | Market Commentary: U.S. Steel notes weaken after CFO departure; PG&E lower amid exclusivity termination
|
10/1/2019 | DD | Market Commentary: U.S. Steel notes lower on acquisition news; Mallinckrodt active in pharmaceutical space
|
9/13/2019 | DD | Market Commentary: PG&E bonds lower on insurance settlement news; Mallinckrodt better in pharma space
|
9/6/2019 | DD | Market Commentary: Mallinckrodt mixed on settlement news; PG&E better in run-up to restructuring plan
|
9/5/2019 | DD | Market Commentary: Mallinckrodt sinks on restructuring talk; Bed Bath better after announcing revamp plan
|
8/27/2019 | HY | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
8/27/2019 | DD | Market Commentary: Endo, Teva drop post-settlement news; Range Resources active, flat after downgrade
|
8/26/2019 | HY | Market Commentary: Endo higher in pharma space; SRC Energy jumps on acquisition news; Dish better
|
8/26/2019 | HY | Market Commentary: Endo, Mallinckrodt notes better on settlement news; DISH rises after analyst upgrade
|
8/26/2019 | DD | Market Commentary: Endo, Mallinckrodt notes better on settlement news; DISH rises after analyst upgrade
|
8/23/2019 | HY | Market Commentary: Oil names negative; Sinclair, L Brands mixed; $10.4 billion of inflows; indexes better
|
8/23/2019 | DD | Market Commentary: L Brands bonds lower after analyst downgrade; Endo paper declines in pharma space
|
8/22/2019 | DD | Market Commentary: L Brands bonds active, mixed after earnings report; CBL eyed after delisting notice
|
8/21/2019 | HY | Market Commentary: Elanco varies after animal health buyout news; oil names trend positive; PG&E rises
|
8/21/2019 | DD | Market Commentary: L Brands lower on earnings anticipation; Endo International notes continue to rise
|
8/20/2019 | HY | Market Commentary: PG&E continues to decline; Endo gains after settling suit; Tenet varies
|
8/20/2019 | DD | Market Commentary: Endo International gains after lawsuit settlement news; PG&E weakens in utilities space
|
7/1/2019 | HY | Market Commentary: CSC Holdings prices; Western Digital gains; Endo drops; Coty down on restructuring
|
3/26/2019 | BKCVDDEMIGPV | Market Commentary: Allison Transmission oversubscribed; Endo, Par Pharma jump; Bed Bath & Beyond surges
|
3/26/2019 | HY | Market Commentary: Allison Transmission oversubscribed; Endo, Par Pharma jump; Bed Bath & Beyond surges
|
3/15/2019 | BKCVDDEMIGPV | Market Commentary: Power Solutions carries over; SS&C Technologies, Par in focus; Community Health drops
|
3/15/2019 | HY | Market Commentary: Power Solutions carries over; SS&C Technologies, Par in focus; Community Health drops
|
3/15/2019 | HY | Market Commentary: Morning Commentary: Power Solutions megadeal eyed; new Par Pharma notes post gains
|
3/14/2019 | BKCVDDEMIGPV | Market Commentary: SS&C Technologies, Endo price; Amkor, Ashton Woods trade up; funds add $1.04 billion
|
3/14/2019 | HY | Market Commentary: SS&C Technologies, Endo price; Amkor, Ashton Woods trade up; funds add $1.04 billion
|
3/14/2019 | DD | Market Commentary: Endo notes positive as company begins debt refinancing; PHI issues dip over maturity fears
|
3/14/2019 | HY | New Issue: Endo/Par Pharmaceutical sells upsized $1.5 billion eight-year notes at par to yield 7˝%
|
3/14/2019 | BKDDHY | Moody’s cuts Endo debt, rates revolver, notes Ba3
|
3/14/2019 | BKDDHY | S&P trims Endo International, rates Par Pharma notes B+
|
3/14/2019 | HY | Endo/Par Pharmaceutical to sell $1 billion eight-year notes Thursday
|
10/5/2015 | BK | S&P ups Par Pharmaceutical, withdraws ratings
|
9/21/2015 | HYLM | Par Pharmaceutical plans to redeem 7 3/8% notes due 2020 on Sept. 30
|
5/20/2015 | BKHY | S&P puts Par Pharmaceuticals on positive watch
|
5/18/2015 | CLHY | Market Commentary: WideOpenWest, Aria Energy break; Par Pharmaceutical loans slide with acquisition by Endo
|
5/18/2015 | BK | Market Commentary: WideOpenWest, Aria Energy break; Par Pharmaceutical loans slide with acquisition by Endo
|
5/18/2015 | BKHY | Moody’s could lift Par Pharma
|
2/19/2015 | BK | Market Commentary: PetSmart, Par Pharmaceutical break; Waste Industries, Veresen, BATS, Healogics tweak deals
|
2/19/2015 | CLHY | Market Commentary: PetSmart, Par Pharmaceutical break; Waste Industries, Veresen, BATS, Healogics tweak deals
|
2/19/2015 | BK | Par Pharmaceutical cuts spread on term loan B-3 to Libor plus 325 bps
|
2/10/2015 | BK | Market Commentary: AssuredPartners breaks; Panda Temple, Par Pharmaceutical release talk; Healogics floats OID
|
2/10/2015 | CLHY | Market Commentary: AssuredPartners breaks; Panda Temple, Par Pharmaceutical release talk; Healogics floats OID
|
2/10/2015 | BK | Par Pharmaceutical talks $425 million loan at Libor plus 375-400 bps
|
2/10/2015 | BKDDHY | Moody's changes Par to stable, rates add-on B1
|
2/9/2015 | BK | Market Commentary: Citgo Holding, Phoenix Services hit secondary; PetSmart reveals pricing guidance with launch
|
2/9/2015 | CLHY | Market Commentary: Citgo Holding, Phoenix Services hit secondary; PetSmart reveals pricing guidance with launch
|
2/9/2015 | BKHY | S&P rates Par Pharma loan B
|
2/9/2015 | BK | Par Pharmaceutical readies launch of new loan for Tuesday
|
2/5/2014 | BK | Par Pharmaceutical firms $1.45 billion term loan at Libor plus 300 bps
|
2/5/2014 | BK | Market Commentary: Par Pharma, SBA, Chrysler, Dunkin', NewPage, ExGen break; Ziggo, PeroxyChem, Bob's reworked
|
2/3/2014 | BKDDHY | S&P cuts Par Pharmaceutical
|
1/30/2014 | BK | Moody's gives Par loan B1
|
1/29/2014 | BK | Market Commentary: Atrium, Mergermarket, National Mentor break; multiple primary deals see revisions emerge
|
1/29/2014 | BK | Par Pharmaceutical launches $395 million add-on term loan, repricing
|
1/28/2014 | BK | Par Pharmaceuticals to hold loan lender call on Wednesday
|
1/22/2014 | BKHY | S&P: Par Pharmaceutical on negative watch
|
1/21/2014 | BK | Par Pharmaceutical gets commitments for $505 million of debt financing
|
2/1/2013 | BK | Market Commentary: ABB Concise, Summit, Genesys, Hamilton Sundstrand, Go Daddy, Par Pharmaceutical, IMS break
|
1/31/2013 | BKHY | S&P rates Par loan B+
|
1/28/2013 | BK | Par Pharmaceutical launches term loan repricing at Libor plus 325 bps
|
1/28/2013 | BK | Market Commentary: Ocwen Loan Servicing breaks; DineEquity tweaks deal; SESAC, Crossmark shutting early
|
1/25/2013 | BK | Par Pharmaceutical to hold credit facility lender call on Monday
|
10/19/2012 | BKHY | S&P: Par Pharmaceuticals loan B+, notes B-
|
9/28/2012 | BK | Market Commentary: Calpine, Level 3, GNC, Univar, Tank Holding break; iStar down with refi; Transtar to shut early
|
9/19/2012 | HY | Market Commentary: Nationstar, AOT deals price, move up, Hovnanian, Intelsat also drive by; calendar swells
|
9/18/2012 | BKHY | S&P: Par Pharmaceutical unchanged
|
9/18/2012 | HY | New Issue: Par Pharma prices $490 million eight-year notes at par to yield 7 3/8%
|
9/18/2012 | HY | Market Commentary: PDVSA bonds active, soft; FMG's new loan helps bonds, stock; Patriot Coal dips; ResCap rises
|
9/17/2012 | HY | Par Pharma talks $490 million eight-year notes with 71/2% area yield
|
9/17/2012 | HY | Market Commentary: High-yield market muted due to holiday; Navistar downgraded, bonds little changed; Sprint firms
|
9/17/2012 | BK | Par Pharmaceutical upsizes loan to $1.06 billion, tightens spread talk
|
9/17/2012 | BK | Market Commentary: Getty Images sets bank meeting; Par Pharma upsizes; LCDX unchanged during holiday session
|
9/11/2012 | HY | Par Pharma provides details on $490 million eight-year notes offering
|
9/11/2012 | HY | Market Commentary: D.R. Horton, Hiland price; Horton yields early gains; new NRG up; overall market firmer
|
9/7/2012 | HY | Market Commentary: Tesoro, Hub price to cap over $5 billion week; new deals mostly up by 2 points
|
9/7/2012 | BK | Par Pharmaceutical talks $980 million loan at Libor plus 425-450 bps
|
9/7/2012 | BK | Market Commentary: Chemtura softens with add-on; CNO, Burger King, Payless, Par Pharmaceutical set talk
|
9/7/2012 | HY | Par Pharmaceutical expected to kick off $490 million notes on Thursday
|
9/6/2012 | BK | Moody's rates Sky Growth
|
9/6/2012 | BKHY | S&P rates Par Pharmaceuticals loan B+, notes B-
|
9/4/2012 | BK | Par Pharmaceutical sets Thursday launch for $1.13 billion facility
|
9/4/2012 | BK | Market Commentary: Claire's Stores rises with paydown; Valeant dips on acquisition; FoxCo, Ikaria set talk
|
8/31/2012 | BK | Market Commentary: Investors await pickup in primary activity with acquisition/LBO deals post-Labor Day
|
8/22/2012 | HY | Par Pharma expected to bring $490 million notes by mid-September
|
8/22/2012 | HY | Market Commentary: Primary quiet, though Par Pharmaceuticals seen planning deal; VWR firm again, ATP still busy
|
8/22/2012 | BK | Par Pharmaceutical $1.13 billion facility anticipated for September
|
8/2/2012 | BKHY | Par Pharma plans $1.13 billion loan, $490 million bridge for buyout
|
7/16/2012 | BK | Par Pharmaceutical plans new debt via three banks for buyout by TPG
|
11/18/2011 | BK | Par Pharmaceutical enters $450 million facility for Anchen purchase
|
8/24/2011 | BK | Par Pharmaceutical plans $450 million facility for Anchen purchase
|
8/24/2011 | BK | Market Commentary: Avis term loan B syndication may slide into September; Par Pharmaceutical readies deal
|
11/25/2009 | CV | Par Pharmaceutical holders tender $30.81 million 2.875% convertibles
|
11/9/2009 | CV | Par extends tender offer for 2.875% convertibles, increases price
|
10/14/2009 | CV | Par begins modified Dutch auction tender offer for 2.875% convertibles
|
8/4/2009 | CV | Par Pharmaceutical buys back $49.3 million of its convertible debt
|
6/25/2009 | CVDD | Par Pharmaceutical avoids acceleration of 2.875% convertibles
|
6/19/2009 | CVIG | Par Pharmaceutical files $150 million shelf for stock, debt, warrants
|
11/6/2008 | CV | Par Pharma buys back $58 million of 2.875% convertible notes due 2010
|
10/6/2006 | BTCVDD | Par Pharmaceutical receives acceleration notice on $200 million 2.875% convertibles
|
9/13/2006 | BT | Unimed, Watson, Par settle AndroGel testosterone gel patent litigation
|
9/6/2006 | BTCVDD | Par Pharmaceutical receives disputed default notice on 2.875% convertibles
|
8/1/2006 | CV | Market Commentary: Kodak holds against outlook; Scottish Re calms nerves; Itron gains off the blocks; GM declines
|
7/24/2006 | BT | Par Pharmaceuticals subject to informal SEC investigation
|
7/19/2006 | BT | Par Pharmaceutical gets OK to market meloxicam for osteoarthritis
|
7/18/2006 | CV | Market Commentary: Avnet improves on Lehman recommendation; Sanmina-SCI unmoved by warning; New River plans deal
|
7/7/2006 | BT | Market Commentary: LifeCell lower; CV Therapeutics loses 2%; Indevus up; Tercica off by 8%; Amarillo Biosciences off
|
7/7/2006 | CV | Market Commentary: PMC-Sierra trips on outlook, CFO's resignation; General Motors up on meeting; Par Pharmaceutical eases
|
7/6/2006 | BT | Market Commentary: Par shares plunge, convertible up with restatement; Savient up on new CFO; Gene Logic moves up
|
7/6/2006 | CV | Market Commentary: Par Pharmaceutical gains amid restatements; Openwave slips on weak forecast; tech names better bid
|
7/5/2006 | BT | Par Pharmaceutical to restate financial results
|
6/30/2006 | BT | Par Pharmaceutical to sell Tranylcypromine sulfate tablets for treatment of depression
|
5/30/2006 | BT | Par Pharmaceutical unit granted final FDA approval for generic product for constipation
|
5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
3/29/2006 | CV | Market Commentary: Lear gains on financing news, Amdocs strengthens; new issue from AMG fails to enthuse
|
3/7/2006 | BT | Par Pharmaceutical resumes shipment of generic Flonase
|
2/28/2006 | CV | Market Commentary: Mentor Graphics up on debut; Citadel down on challenge by bondholders; ArvinMeritor to price new deal
|
2/24/2006 | BT | Market Commentary: Corautus, Cepheid deals emerge; BioMarin bounces; GCP gains on PIPEs deal; Par pounced on news
|
2/24/2006 | BT | Par Pharmaceutical halts shipment of generic Flonase
|
2/23/2006 | BT | Par Pharmaceutical begins shipment of generic Flonase
|
2/23/2006 | BT | Spectrum, Par form alliance to develop, market generic drugs
|
1/26/2006 | BT | Par Pharmaceutical divests active ingredient-maker FineTech
|
12/30/2005 | BT | Par receives FDA approval for generic version of Cefzil antibiotic
|
12/30/2005 | BT | Par gets FDA approval for cabergoline, generic of Pfizer's Dostinex to treat hyperprolactinemic disorders
|
12/23/2005 | BT | Par gets FDA approval for Cefprozil, generic of Bristol-Myers antibiotic
|
12/23/2005 | BT | Market Commentary: Progenics, Wyeth rise on $416.5 million pact; Par Pharma higher; AtheroGenics gains further 7%
|
12/22/2005 | BT | Par to buy eight generics from Teva, Ivax
|
12/19/2005 | BT | Par: Study shows MA-CS 575 causes faster weight gain than Megace MA-OS 800 in HIV patients
|
12/19/2005 | BT | Par says studies show PAR-101 appears to be effective in treating C.difficile-associated diarrhea
|
12/16/2005 | CV | Market Commentary: OSI Pharmaceuticals new issue rises, but ON Semiconductor slips; Carnival lower on higher dividend fears
|
12/16/2005 | BT | Par assigned Ivax's U.S. distribution rights for Augmentin, Amoxil generics
|
12/14/2005 | BT | Bradley, Par form licensing, distribution agreement for Adoxa antibiotic
|
12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
12/5/2005 | BT | Par, Three Rivers and Teva say FDA approved ribavirin, generic of Roche's Copegus to treat hepatitis C
|
12/1/2005 | BT | Par gets tentative FDA approval for generic Dostinex
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/30/2005 | BT | Par Pharmaceutical partners with IntelliPharmaCeutics to develop generic drug for U.S. market
|
11/21/2005 | BT | Par receives FDA approval and marketing exclusivity for ondanestron tablets
|
11/21/2005 | BT | Market Commentary: Incyte zooms on R&D pact with Pfizer; Medicis, Mentor, Allergan, Inamed tangle in merger scuffle
|
11/3/2005 | BT | Par and Valeant to co-promote Cesamet for chemotherapy-induced nausea and vomiting
|
10/27/2005 | BT | Market Commentary: NxStage soars on IPO debut; Durect launches equity deal; Cell Therapeutics deal abuzz; Amylin plunges
|
10/27/2005 | CV | Market Commentary: GM bonds lower, credit widens on bankruptcy scare; Digital River plunges; Par Pharma in
|
10/24/2005 | BT | Par enters strategic relationship with Turkey's MN Pharmaceuticals
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
10/20/2005 | BT | Par announces tentative approval of generic ribavirin
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
10/11/2005 | CV | Market Commentary: GM, Ford trade mixed, but remain market focus; Skyworks holds up after lower guidance; Inco rises
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
9/1/2005 | CV | Market Commentary: Airtran, Northwest lead airline convertibles lower; autos sink; Chiron, Phar Pharma gain
|
8/18/2005 | CV | Market Commentary: Six Flags selling on upswing from Snyder's move; Northwest, Delta drift higher, Charming Shoppes up
|
8/18/2005 | BT | Market Commentary: Myogen shoots higher on trial data; Par Pharma buyers hoping for deal; Del Labs bonds fall; Cephalon up
|
7/28/2005 | BT | Market Commentary: Advanced Life Sciences IPO cut; ZymoGenetics plans follow-on; Elan plunges on credit worries
|
7/28/2005 | CV | Market Commentary: L-3's new convertibles take market focus, Northwest Airlines gains; FTI deal prices after close
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
2/22/2005 | CV | Market Commentary: Level 3 converts rise on private deal; UniSource, Allied Waste deals emerge; Par, Ivax, Teva up
|
11/23/2004 | CV | Market Commentary: Sirius soars on numbers; XM rides wave higher too; Disney easier; Par Pharma trades up
|
7/7/2004 | CV | Market Commentary: Omnicom, AMG spiral on new CoCo rule possibility; EDS active on tighter credit
|